Indications for Sitagliptin/Metformin Hydrochloride Extended-Release Tablets (Janumet XR)-Seagull Pharmacy

new

Indications for Sitagliptin/Metformin Hydrochloride Extended-Release Tablets (Janumet XR)

502

Article source: Seagull Pharmacy

Nov 06, 2025

Sitagliptin/Metformin Hydrochloride Extended-Release Tablets (Janumet XR) is an innovative oral combination anti-diabetic formulation that integrates the dual advantages of a dipeptidyl peptidase-4 (DPP-4) inhibitor and a biguanide agent.

Indications for Sitagliptin/Metformin Hydrochloride Extended-Release Tablets (Janumet XR)

Primary Indication

Adjunctive treatment for type 2 diabetes in adults: Serving as an effective supplement to dietary control and exercise therapy, it is specifically indicated to improve blood glucose control in adult patients with type 2 diabetes.

Special Precautions

Contraindicated Populations: It must not be used for the treatment of patients with type 1 diabetes.

Risk of Pancreatitis: No systematic studies have been conducted in patients with a history of pancreatitis, so it cannot be determined whether the use of this drug in such patients will increase the risk of developing pancreatitis. A rigorous assessment of medication safety is necessary.

Dosage Strengths and Physical Characteristics of Sitagliptin/Metformin Hydrochloride Extended-Release Tablets (Janumet XR)

Sitagliptin 100 mg / Metformin Hydrochloride 1000 mg Extended-Release Tablets

Physical Appearance: Blue, biconvex, oval-shaped film-coated tablets.

Identification Marking: Imprinted with the code "81" on one side as an anti-counterfeiting mark.

Sitagliptin 50 mg / Metformin Hydrochloride 500 mg Extended-Release Tablets

Physical Appearance: Light blue, biconvex, oval-shaped film-coated tablets.

Identification Marking: Imprinted with the code "78" on one side.

Sitagliptin 50 mg / Metformin Hydrochloride 1000 mg Extended-Release Tablets

Physical Appearance: Light green, biconvex, oval-shaped film-coated tablets.

Identification Marking: Imprinted with the code "80" on one side.

Storage Instructions for Sitagliptin/Metformin Hydrochloride Extended-Release Tablets (Janumet XR)

Temperature Control Standards

Ideal Storage Temperature: 20°C to 25°C (68°F to 77°F).

Allowable Temperature Fluctuation Range: 15°C to 30°C (59°F to 86°F).

Storage Environment Requirements: Store in a dry area with the container tightly sealed.

Key Points for Packaging Management

Maintenance of Original Packaging: The original packaging must be retained, and the bottle cap must be kept tightly closed.

Child Safety Protection: Store the product in an area that is out of the reach of children.

Usage and Handling Specifications: Reseal the container immediately after each dose is taken.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.

Recommended Articles

What Are the Side Effects of Tivozanib (Fotivda)?

Tivozanib (Fotivda) is a targeted therapy drug for recurrent or refractory advanced renal cell carcinoma, offering new hope to patients who have undergone multiple lines of systemic treatment. However...

Precautions for Administration of Tivozanib (Fotivda)

Tivozanib (Fotivda) is a kinase inhibitor. By targeting multiple tyrosine kinase targets such as vascular endothelial growth factor receptor (VEGFR), it inhibits tumor angiogenesis and is used for the...

How to Use Tivozanib (Fotivda)

Tivozanib (Fotivda) is a kinase inhibitor that was first approved in the United States in 2021. This medication is specifically indicated for the treatment of adult patients with advanced renal cell c...

Indications for Tivozanib Capsules (Fotivda)

Tivozanib Capsules (Fotivda) is a kinase inhibitor that was first approved in the United States in 2021. As an important drug for the treatment of advanced renal cell carcinoma, it blocks tumor angiog...

How to Use Sitagliptin/Metformin Hydrochloride Extended-Release Tablets (Janumet XR)

Sitagliptin/Metformin Hydrochloride Extended-Release Tablets (Janumet XR) is a fixed-dose combination antihyperglycemic medication. It contains sitagliptin (a dipeptidyl peptidase-4 inhibitor) and met...

What Are the Side Effects of Sitagliptin/Metformin Hydrochloride Extended-Release Tablets (Janumet XR)?

Sitagliptin/Metformin Hydrochloride Extended-Release Tablets (Janumet XR) is a fixed-dose combination preparation for the treatment of type 2 diabetes. It provides effective blood glucose control for ...

How to Purchase Enstilar

Enstilar is a prescription medication and must be obtained in strict compliance with medical regulatory procedures. It contains calcipotriene (a vitamin D analog) and betamethasone dipropionate (a cor...

Indications for Enstilar

Enstilar is an innovative topical fixed-dose combination preparation that integrates the dual effects of a vitamin D analog and a corticosteroid, specifically designed for the treatment of plaque psor...

Dosage and Administration, Recommended Dosage of Capmatinib (Tabrecta)

Capmatinib (Tabrecta) is a highly selective MET inhibitor, offering a precision treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation...

What Are the Indications for Capmatinib (Tabrecta)?

Capmatinib (Tabrecta) is a targeted therapy medication that plays an important role in the treatment of non-small cell lung cancer associated with specific gene mutations. As a MET kinase inhibitor, i...

What Are the Purchase Channels for Capmatinib (Tabrecta)?

Capmatinib (Tabrecta) is a highly selective MET inhibitor that has demonstrated significant efficacy in patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutat...

Adverse Reactions of Ivosidenib (Tibsovo)

Ivosidenib (Tibsovo) is an isocitrate dehydrogenase 1 (IDH1) inhibitor, primarily indicated for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and cholangiocarcinoma...

What Are the Precautions for Using Ivosidenib (Tibsovo)?

Ivosidenib (Tibsovo) is a targeted therapy medication primarily indicated for the treatment of patients with malignant hematologic diseases harboring specific gene mutations.What Are the Precautions f...

Dosage and Administration, Recommended Dosage of Ivosidenib (Tibsovo)

Ivosidenib (Tibsovo) is a targeted isocitrate dehydrogenase 1 (IDH1) inhibitor that demonstrates significant value in the treatment of malignant tumors with specific gene mutations.Dosage and Administ...

What Are the Indications for Ivosidenib (Tibsovo)?

Ivosidenib (Tibsovo) is an oral isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with various malignant tumors harboring specific IDH1 gene mutations. By inhibiting the activity of m...

What Are the Purchase Channels for Ivosidenib (Tibsovo)?

Ivosidenib (Tibsovo) is an important targeted therapy drug against IDH1 mutations, demonstrating significant efficacy in diseases such as acute myeloid leukemia and cholangiocarcinoma. For patients in...

Core Drugs